Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PATRICK HWU and WILLEM OVERWIJK.
PATRICK HWU
Connection Strength
1.846
WILLEM OVERWIJK
  1. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447.
    View in: PubMed
    Score: 0.152
  2. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
    View in: PubMed
    Score: 0.123
  3. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86.
    View in: PubMed
    Score: 0.111
  4. Persistent antigen at vaccination sites induces tumor-specific CD8? T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr; 19(4):465-72.
    View in: PubMed
    Score: 0.110
  5. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.
    View in: PubMed
    Score: 0.107
  6. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009 Jun 15; 182(12):7398-407.
    View in: PubMed
    Score: 0.085
  7. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14342-6.
    View in: PubMed
    Score: 0.081
  8. Correction: IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2024 Feb 01; 212(3):500.
    View in: PubMed
    Score: 0.059
  9. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022 07 01; 132(13).
    View in: PubMed
    Score: 0.053
  10. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.050
  11. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 2001 Nov 01; 61(21):7920-4.
    View in: PubMed
    Score: 0.050
  12. IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975.
    View in: PubMed
    Score: 0.048
  13. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021 08; 11(8):1996-2013.
    View in: PubMed
    Score: 0.048
  14. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother. 2021 Apr; 70(4):1101-1113.
    View in: PubMed
    Score: 0.047
  15. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661.
    View in: PubMed
    Score: 0.044
  16. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.
    View in: PubMed
    Score: 0.038
  17. Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res. 2017 Oct 15; 23(20):6151-6164.
    View in: PubMed
    Score: 0.037
  18. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017 Aug; 27(8):1034-1045.
    View in: PubMed
    Score: 0.037
  19. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. J Immunother. 2017 01; 40(1):11-20.
    View in: PubMed
    Score: 0.036
  20. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
    View in: PubMed
    Score: 0.036
  21. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol Res. 2016 11; 4(11):983-994.
    View in: PubMed
    Score: 0.035
  22. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.035
  23. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.033
  24. Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype. Am J Dermatopathol. 2013 Apr; 35(2):184-90.
    View in: PubMed
    Score: 0.028
  25. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.027
  26. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.027
  27. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.
    View in: PubMed
    Score: 0.027
  28. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-? inducible chemokines. Cancer Res. 2012 Oct 15; 72(20):5209-18.
    View in: PubMed
    Score: 0.027
  29. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82.
    View in: PubMed
    Score: 0.026
  30. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
    View in: PubMed
    Score: 0.024
  31. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
    View in: PubMed
    Score: 0.024
  32. Induction of TLR4-dependent CD8+ T cell immunity by murine ?-defensin2 fusion protein vaccines. Vaccine. 2011 Apr 18; 29(18):3476-82.
    View in: PubMed
    Score: 0.024
  33. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68.
    View in: PubMed
    Score: 0.023
  34. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009 Nov 20; 31(5):787-98.
    View in: PubMed
    Score: 0.022
  35. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8.
    View in: PubMed
    Score: 0.021
  36. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75.
    View in: PubMed
    Score: 0.019
  37. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
    View in: PubMed
    Score: 0.019
  38. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14; 25(46):7955-61.
    View in: PubMed
    Score: 0.019
  39. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006 Aug 15; 12(16):4794-803.
    View in: PubMed
    Score: 0.017
  40. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2359s-2365s.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.